Business Standard

Saturday, January 04, 2025 | 06:59 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Bharat Biotech's intranasal vaccine gets regulator nod for Phase 2/3 trials

It is the first nasal vaccine in the country that has received the regulatory approval for late-stage clinical trials

A health worker collects a nasal sample for Covid-19 Ag rapid antigen testing at Chakkarpur Community Centre, near DLF Phase 4, in Gurugram
Premium

BS Web Team
The intranasal vaccine against coronavirus being developed by Bharat Biotech and supported by Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance Council (BIRAC) has got the regulator nod for Phase 2-3 trials.

Bharat Biotech's intranasal vaccine is the first nasal vaccine in the country that has received the regulatory approval for Phase 2/3 trials, the Ministry of Science and Technology said in a statement.

"This is the first of its kind Covid-19 jab to undergo human clinical trials in India. BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.BBIL has in-licensed technology from Washington University in St Louis,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in